• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Scancell appoints Dr Jean-Michel Cosséry as Non-Executive Chairman of the Board

by admin | Feb 1, 2023 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Interim Results for the 6 months ended 31 October 2022

by admin | Jan 25, 2023 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Citrullinated glucose-regulated protein 78 is a candidate target for melanoma immunotherapy

by admin | Dec 9, 2022 | Moditope, Vaccines

Victoria Anne Brentville, Peter Symonds, JiaXin Chua, Anne Skinner, Ian Daniels, Katherine Wendy Cook, Sasa Koncarevic, Roxana Martinez-Pinna, Sabaria Shah, Ruhul Hasan Choudhury, Poonam Vaghela, Daisy Weston, Abdullah Al-Omari, James Davis and Lindy G. Durrant...

Result of Annual General Meeting

by admin | Nov 23, 2022 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

14th Annual Meeting of the Protein & Antibody Engineering Summit (PEGS), 14-16 November 2022 in Barcelona, Spain

by admin | Nov 16, 2022 | Antibodies, Avidimab

Bubacarr G Kaira, Foram Dave, Elena Dubinina, Omar Mohammed, Bryony Heath, Poonam Vaghela, Ruhul Choudhury, Tina Parsons, Samantha Paston and Mireille Vankemmelbeke and Lindy G. Durrant
« Older Entries
Next Entries »

Recent Posts

  • Active Immunotherapy: Ready For Prime Time
  • Strategic transactions to unlock longer-term value
  • Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
  • iSCIB1+ pivotal trial plans advancing
  • AACR (American Association for Cancer Research) Annual Meeting, April 2026, San Diego, California

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy